← All candidates
One insider buy in the last year — $9.00M in all.
102 filings on record.
MIRMMirum Pharmaceuticals, Inc.
NasdaqGM · Healthcare · $6.32B
$97.37
+3.70% today
One insider buy in the last year — $9.00M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 42 sells◆ 9 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$6.32B
Float
56.4M
87% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
10.2
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Heron Patrick J
Bought $9.00M on Jan 23 — 131,425 sh @ $68.48, held indirect, 29% of their stake.
3 of 3 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
97 more transactions on Pro →Context
Wall St
$146.07 avg target
+50.0% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.08 act−$0.73
Q4 '25−$0.12 act−$0.18
Q3 '25$0.05 act+$0.21
Q2 '25−$0.12 act+$0.21
Coverage
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug ZilurgisertibSimply Wall St. · 07-02Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?Zacks · 06-29Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?Insider Monkey · 06-25MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Zacks · 06-17
The file stays open
102 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice